This report highlights the keys to a sucessful theraputics company as part of an overview of the current landscape for outsourcing therapeutics development in Canada.

Will millennials will make an impact on Canada’s biotechnology sector?

Life sciences investment banker, Tony Pullen, follows up with his third report on the state of Canada’s public life sciences companies.

This roundtable report discusses the implications of the Comprehensive Economic and Trade Agreement signed by Canada and the European Union.

Biotechnology Focus readers put forth their Innovation Agenda priorities via our Hot Button Issue Survey summary.

Robert Merson highlights some of the factors that drive student scientists to cross over into the world of business, the tools that get them there, and which bioscience entrepreneurs and companies to watch going forward.

Outsourcing, it’s more than a trend in biotech, it’s a means of survival. In this special report, we ask three Canadian biotech C-level executives to weigh in on the keys to enjoying a successful relationship with their outsourcing partners, some of the ins-and-outs so to speak, as well as why outsourcing is an integral piece to their collective business plans.

First-of-its-kind employee survey of Canada’s biotechnology industry brings future of industry into focus

High-speed photography is a challenge even for the most talented of photographers. This is because when things move fast they can be difficult to capture—even for a snapshot. Human Resource (HR) professionals in rapidly expanding industries, like the biotechnology and life science industries, face a similar problem. How can you capture and understand that which is constantly moving and changing?

A special report on what’s going on in Canada as it relates to regulations and policies governing clinical trials, and how we as a nation stack up in the global competition for clinical trial investment.

Tony Pullen’s long awaited follow up piece revisiting the question: Is Canada’s biotech sector showing new life like its U.S. counterparts? Or was last year’s promising market activity much ado about nothing?

(Part One of a series by Tony Pullen, a veteran of the Canadian capital markets)

I have been wondering for months and months if (and maybe even when) the strong advances that have occurred since last fall in the U.S. biotech market might trigger a rally in their Canadian brethren. I had pretty much abandoned hope – until these recent stirrings. The case for a Canadian bull market in the space is that valuations reappearing down south will make for heady comparisons to similar science north of the border.